Arlington Capital Partners-backed AVS Bio has acquired Biorbyt, a UK supplier of bio-reagents, antibodies, proteins and other biomaterials for life science research. The deal expands AVS Bio's product catalog and global distribution through Biorbyt's e-commerce platform.

Founded in 2011 and headquartered in Cambridge, UK, Biorbyt maintains a catalog of more than 1 million SKUs spanning primary and secondary antibodies, recombinant and native proteins, ELISA kits, small molecules and molecular biology reagents. Biorbyt will continue operating under its existing leadership as part of the AVS Bio platform.

AVS Bio, headquartered in Norwich, Connecticut, provides biological materials and services supporting the development and manufacture of vaccines, therapeutics and biologics. It is a portfolio company of Arlington Capital Partners, a Washington, D.C.-area private investment firm focused on government-regulated industries. "Biorbyt is highly complementary to AVS Bio's capabilities and will materially broaden its product offering while adding digital commerce capabilities," said Malcolm Little, partner at Arlington Capital Partners.